Gundersen Lutheran Proposal to Join the Community Clinical Oncology Program

冈德森路德教会关于加入社区临床肿瘤学计划的提案

基本信息

  • 批准号:
    8145432
  • 负责人:
  • 金额:
    $ 57.45万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2011
  • 资助国家:
    美国
  • 起止时间:
    2011-07-26 至 2014-05-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The Gundersen Lutheran Center for Cancer and Blood Disorders, located in La Crosse, Wisconsin, provides cancer care for a predominantly rural population of 560,000 comprising 19 counties in western Wisconsin, northeastern lowa, and southeastern Minnesota. A substantial proportion of the population served in this Tri- state area is considered a Medically Underserved Population or lives in a Health Professional Shortage Area, as designated by the Department of Health and Human Services (DHHS). Of the counties outside of La Crosse, 70%, 60%, 20%, and 5% are considered underserved by DHHS due to geographical area, low income, presence of a correctional facility, or having a Native American tribal population, respectively. Approximately 3% of the population is from ethnic minority groups including Hmong, Native American, and Hispanic. The core of the proposed Community Clinical Oncology Program (CCOP) will be composed of 5 medical oncologists, 4 hematologists, and 4 radiation oncologists, all of whom are employed by the same health system. The group has a strong history of clinical research, with over 30 years of clinical trial experience enrolling over 1200 patients into National Cancer Institute (NCI) (ECOG, RTOG, COG, GOG, ACOSOG, and CTSU) and industry-sponsored trials. In alignment with and complementary to its NCI National Community Cancer Centers Program, the proposed CCOP will enhance clinical trial accrual among the population it serves with the following action plans: 1) offer clinical trial access to a wider geographic area by implementing research infrastructures in rural outreach sites; 2) increase accrual to cancer control/prevention and treatment trials by forming affiliations with new CCOP research bases; 3) improve research participation of minority groups by providing education and cancer screening opportunities; and 4) enhance clinical trial participation (especially to cancer control/prevention trials) among care providers from other medical specialties by regularly promoting clinical trial awareness during various multidisciplinary cancer conferences. We expect to exceed the minimum number of required accrual and meet standard requirements for quality assurance and human subject safety. RELEVANCE: Our proposed CCOP will provide and enhance clinical trial access to a rural population in the Midwest, predominantly underserved due to geographical barriers. Several pockets of minority groups (Native American, Hmong, and Hispanic) across a wide area will also be targeted.
描述(由申请人提供):位于威斯康星州拉克罗斯市的Gundersen Lutheran癌症和血液疾病中心,为主要的560,000人口提供了癌症护理,其中包括19个县,在威斯康星州西部,洛亚东北部和明尼苏达州东南部。在该三州地区服务的人口中,很大一部分被认为是医疗服务不足的人口,或者居住在卫生和公共服务部(DHHS)指定的卫生专业短缺地区。在La Crosse以外的县中,由于地理区域,低收入,惩教设施的存在或拥有美洲原住民部落人口,DHHS被认为是DHH的70%,60%,20%和5%。大约3%的人口来自包括苗族,美洲原住民和西班牙裔在内的少数民族。拟议的社区临床肿瘤学计划(CCOP)的核心将由5位医学肿瘤学家,4位血液学家和4位放射性肿瘤学家组成,所有这些肿瘤学家均由同一卫生系统雇用。该小组拥有悠久的临床研究历史,拥有30多年的临床试验经验,将1200多名患者纳入国家癌症研究所(NCI)(ECOG,RTOG,COG,GOG,ACOG,ACOSOG和CTSU)和行业赞助的试验。在与其NCI国家社区癌症中心计划的一致性和互补的情况下,拟议的CCOP将在其服务于以下行动计划的人群中加强临床试验:1)通过在农村外展现场实施研究基础设施,为更广泛的地理领域提供临床试验访问权限; 2)通过与新的CCOP研究基础形成隶属关系来增加对癌症控制/预防和治疗试验的应计; 3)通过提供教育和癌症筛查机会来改善少数群体的研究参与; 4)通过在各种多学科癌症会议期间定期促进临床试验意识,从其他医学专业的护理提供者中增强了临床试验参与(尤其是针对癌症控制/预防试验)。我们预计将超过所需应计的最低数量,并满足质量保证和人类主题安全的标准要求。 相关性:我们拟议的CCOP将在中西部提供并增强对农村人口的临床试验,这主要是由于地理障碍而服务的。广泛地区的几个少数群体(美洲原住民,苗族和西班牙裔)也将成为目标。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Ronald S Go其他文献

Impact of Multiple High-Risk Cytogenetic Abnormalities on the Survival Outcomes of Patients with Primary Plasma Cell Leukemia
  • DOI:
    10.1182/blood-2024-200267
  • 发表时间:
    2024-11-05
  • 期刊:
  • 影响因子:
  • 作者:
    Adrian A Almodovar Diaz;Samhar Alouch;Angela Dispenzieri;Udit Yadav;Francis Buadi;David Dingli;Eli Muchtar;Nelson Leung;Taxiarchis Kourelis;Rahma M Warsame;Ronald S Go;Moritz Binder;Joselle Cook;Miriam Hobbs;Yi Lisa Hwa;Amie Fonder;Michelle G. Rogers;Suzanne R Hayman;Yi Lin;Mustaqeem A. Siddiqui
  • 通讯作者:
    Mustaqeem A. Siddiqui
Improved Survival with Daratumumab-Cybord Compared to Cybord As Frontline Therapy in Immunoglobulin Light Chain (AL) Amyloidosis
  • DOI:
    10.1182/blood-2024-209102
  • 发表时间:
    2024-11-05
  • 期刊:
  • 影响因子:
  • 作者:
    Binoy Yohannan;Matthew James Rees;Morie A. Gertz;Angela Dispenzieri;Francis Buadi;David Dingli;Nelson Leung;Prashant Kapoor;Wilson I. Gonsalves;Taxiarchis Kourelis;Joselle Cook;Moritz Binder;Martha Lacy;Suzanne R Hayman;Yi Lin;Yi Lisa Hwa;Michelle G Rogers;Miriam Hobbs;Amie Fonder;Ronald S Go
  • 通讯作者:
    Ronald S Go
Efficacy of Targeted Agents and Immune Checkpoint Inhibitors in Patients with Malignant Histiocytosis
  • DOI:
    10.1182/blood-2024-204398
  • 发表时间:
    2024-11-05
  • 期刊:
  • 影响因子:
  • 作者:
    Alanis Enid Rodriguez-Rosario;Aldo Adrian Acosta Medina;N. Nora Bennani;Gaurav Goyal;Aishwarya Ravindran;Karen L Rech;Gordon J Ruan;Mithun V Shah;Dongni Yi;Saurabh Zanwar;Jithma P Abeykoon;Ronald S Go
  • 通讯作者:
    Ronald S Go
Assessment of Classical Hematologists and Hematology-Focused Fellowship Programs at NCI-Designated Cancer Centers: Implications for Addressing Workforce Shortages and Enhancing Mentorship Opportunities
  • DOI:
    10.1182/blood-2024-194745
  • 发表时间:
    2024-11-05
  • 期刊:
  • 影响因子:
  • 作者:
    Lewis T Go;Lucas T Go;Madugodaralalaage DSK Gunaratne;Aneel A Ashrani;Michelle A Elliott;Richard C Godby;C Christopher Hook;Leslie J Padrnos;Rajiv K Pruthi;Candido E Rivera;Rachelle L Rouse;Surbhi Shah;Marwan E Shaikh;Mustaqeem A. Siddiqui;Meera Sridharan;Ewa M Wysokinska;Alexandra P Wolanskyj-Spinner;Ronald S Go;Jithma P Abeykoon
  • 通讯作者:
    Jithma P Abeykoon
Characteristics and Outcomes of Patients with Second Hematological Malignancies after Autologous Hematopoietic Cell Transplantation for Multiple Myeloma
  • DOI:
    10.1182/blood-2024-210932
  • 发表时间:
    2024-11-05
  • 期刊:
  • 影响因子:
  • 作者:
    Binoy Yohannan;Angela Dispenzieri;Francis Buadi;David Dingli;Nelson Leung;Prashant Kapoor;Wilson I. Gonsalves;Taxiarchis Kourelis;Joselle Cook;Moritz Binder;Suzanne R Hayman;Yi Lin;Ronald S Go;Rahma M Warsame;Vincent Rajkumar;Shaji Kumar;Eli Muchtar;Hassan B Alkhateeb;William J. Hogan;Mark R. Litzow
  • 通讯作者:
    Mark R. Litzow

Ronald S Go的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Ronald S Go', 18)}}的其他基金

Determining the clinical significance of monoclonal gammopathy of undetermined si
确定未确定的单克隆丙种球蛋白病的临床意义
  • 批准号:
    8719420
  • 财政年份:
    2011
  • 资助金额:
    $ 57.45万
  • 项目类别:
Determining the clinical significance of monoclonal gammopathy of undetermined si
确定未确定的单克隆丙种球蛋白病的临床意义
  • 批准号:
    8265833
  • 财政年份:
    2011
  • 资助金额:
    $ 57.45万
  • 项目类别:
Determining the clinical significance of monoclonal gammopathy of undetermined si
确定未确定的单克隆丙种球蛋白病的临床意义
  • 批准号:
    8114585
  • 财政年份:
    2011
  • 资助金额:
    $ 57.45万
  • 项目类别:

相似海外基金

UCDCCC NCTN U10 Program
UCDCCC NCTN U10 项目
  • 批准号:
    8838065
  • 财政年份:
    2014
  • 资助金额:
    $ 57.45万
  • 项目类别:
Metro-Minnesota Community Clinical Oncology Program (MM-CCOP)
明尼苏达都会区社区临床肿瘤学计划 (MM-CCOP)
  • 批准号:
    8790628
  • 财政年份:
    2014
  • 资助金额:
    $ 57.45万
  • 项目类别:
UCDCCC NCTN U10 Program
UCDCCC NCTN U10 项目
  • 批准号:
    8605734
  • 财政年份:
    2014
  • 资助金额:
    $ 57.45万
  • 项目类别:
UCDCCC NCTN U10 Program
UCDCCC NCTN U10 项目
  • 批准号:
    9128209
  • 财政年份:
    2014
  • 资助金额:
    $ 57.45万
  • 项目类别:
Metro-Minnesota Community Clinical Oncology Program (MM-CCOP)
明尼苏达都会区社区临床肿瘤学计划 (MM-CCOP)
  • 批准号:
    9116801
  • 财政年份:
    2014
  • 资助金额:
    $ 57.45万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了